Viridian Therapeutics, Inc. VRDN
Set alert
24.67 USD -0.13 -0.52%
At close · Oct 30
25.20 +0.53 +2.15%
After hours · Oct 30, 4:46 PM ET
24.14 Day range 25.00
13.30 52-week range 33.78
- YTD
- -20.73%
- 1 year
- +4.27%
- Open
- 24.77
- Prev close
- 24.80
- Mkt cap
- 2.79B
- Vol
- 1.71M
- Avg vol
- 1.80M
- EPS
- -3.39
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 24.14
- High
- 25.00
- Forward P/E
- -9.10
- Beta
- 1.10
- Short ratio
- 8.44
- Inst. own
- 126.55%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 4, 2026
- 50-d avg
- 21.65
- 200-d avg
- 21.80
- 1y target
- 36.20
5D chart
Signals (111)
| Name | Time | Ago |
|---|---|---|
| MACD: Buy Signal | Oct 30, 12:55 PM | 1 day ago |
| SMA: Bullish | Oct 30, 12:45 PM | 1 day ago |
| RSI: Oversold | Oct 30, 12:20 PM | 1 day ago |
| SMA: Bearish | Oct 30, 11:10 AM | 1 day ago |
| MACD: Sell Signal | Oct 30, 11:10 AM | 1 day ago |
| MACD: Buy Signal | Oct 30, 11:05 AM | 1 day ago |
| SMA: Bullish | Oct 30, 10:50 AM | 1 day ago |
| SMA: Bearish | Oct 30, 10:45 AM | 1 day ago |
| SMA: Bearish | Oct 30, 10:45 AM | 1 day ago |
| SMA: Bullish | Oct 30, 10:40 AM | 1 day ago |
| SMA: Bullish | Oct 30, 10:35 AM | 1 day ago |
| SMA: Bearish | Oct 30, 10:10 AM | 1 day ago |
| MACD: Sell Signal | Oct 30, 10:05 AM | 1 day ago |
| SMA: Bearish | Oct 30, 10:00 AM | 1 day ago |
| SMA: Bullish | Oct 29, 3:50 PM | 2 days ago |
| SMA: Bearish | Oct 29, 3:45 PM | 2 days ago |
| SMA: Bullish | Oct 29, 3:10 PM | 2 days ago |
| SMA: Bullish | Oct 29, 3:00 PM | 2 days ago |
| MACD: Buy Signal | Oct 29, 3:00 PM | 2 days ago |
| SMA: Bearish | Oct 29, 2:55 PM | 2 days ago |
| SMA: Bullish | Oct 29, 2:50 PM | 2 days ago |
| MACD: Sell Signal | Oct 29, 2:15 PM | 2 days ago |
| SMA: Bearish | Oct 29, 2:10 PM | 2 days ago |
| SMA: Bearish | Oct 29, 2:10 PM | 2 days ago |
| SMA: Bullish | Oct 29, 2:05 PM | 2 days ago |
| MACD: Buy Signal | Oct 29, 2:00 PM | 2 days ago |
| SMA: Bullish | Oct 29, 1:55 PM | 2 days ago |
| SMA: Bullish | Oct 29, 12:10 PM | 2 days ago |
| SMA: Bearish | Oct 29, 11:45 AM | 2 days ago |
| SMA: Bullish | Oct 29, 11:35 AM | 2 days ago |
| SMA: Bullish | Oct 29, 11:35 AM | 2 days ago |
| SMA: Bearish | Oct 29, 11:30 AM | 2 days ago |
| SMA: Bearish | Oct 29, 11:25 AM | 2 days ago |
| SMA: Bullish | Oct 29, 11:20 AM | 2 days ago |
| MACD: Sell Signal | Oct 29, 10:35 AM | 2 days ago |
| RSI: Overbought | Oct 29, 9:35 AM | 2 days ago |
| SMA: Bullish | Oct 29, 9:30 AM | 2 days ago |
| MACD: Buy Signal | Oct 29, 9:30 AM | 2 days ago |
| SMA: Bearish | Oct 28, 4:00 PM | 3 days ago |
| MACD: Sell Signal | Oct 28, 4:00 PM | 3 days ago |
| MACD: Buy Signal | Oct 28, 3:30 PM | 3 days ago |
| SMA: Bullish | Oct 28, 3:20 PM | 3 days ago |
| SMA: Bearish | Oct 28, 3:10 PM | 3 days ago |
| SMA: Bullish | Oct 28, 3:05 PM | 3 days ago |
| SMA: Bearish | Oct 28, 2:50 PM | 3 days ago |
| MACD: Sell Signal | Oct 28, 2:50 PM | 3 days ago |
| RSI: Overbought | Oct 28, 2:25 PM | 3 days ago |
| RSI: Overbought | Oct 28, 2:15 PM | 3 days ago |
| SMA: Bearish | Oct 28, 1:05 PM | 3 days ago |
| SMA: Bullish | Oct 28, 1:00 PM | 3 days ago |
| MACD: Buy Signal | Oct 28, 12:50 PM | 3 days ago |
| SMA: Bullish | Oct 28, 12:40 PM | 3 days ago |
| SMA: Bearish | Oct 28, 11:25 AM | 3 days ago |
| SMA: Bullish | Oct 28, 11:10 AM | 3 days ago |
| SMA: Bearish | Oct 28, 11:05 AM | 3 days ago |
| MACD: Sell Signal | Oct 28, 11:05 AM | 3 days ago |
| SMA: Bearish | Oct 28, 11:00 AM | 3 days ago |
| SMA: Bullish | Oct 28, 10:45 AM | 3 days ago |
| SMA: Bearish | Oct 28, 10:40 AM | 3 days ago |
| SMA: Bullish | Oct 28, 10:35 AM | 3 days ago |
| SMA: Bearish | Oct 28, 10:30 AM | 3 days ago |
| SMA: Bullish | Oct 28, 9:55 AM | 3 days ago |
| SMA: Bullish | Oct 28, 9:55 AM | 3 days ago |
| SMA: Bearish | Oct 28, 9:35 AM | 3 days ago |
| SMA: Bearish | Oct 28, 9:30 AM | 3 days ago |
| MACD: Buy Signal | Oct 27, 3:50 PM | 4 days ago |
| SMA: Bullish | Oct 27, 3:45 PM | 4 days ago |
| SMA: Bullish | Oct 27, 3:45 PM | 4 days ago |
| SMA: Bearish | Oct 27, 2:55 PM | 4 days ago |
| SMA: Bullish | Oct 27, 2:45 PM | 4 days ago |
| SMA: Bearish | Oct 27, 2:40 PM | 4 days ago |
| MACD: Sell Signal | Oct 27, 2:40 PM | 4 days ago |
| MACD: Buy Signal | Oct 27, 2:00 PM | 4 days ago |
| SMA: Bullish | Oct 27, 1:55 PM | 4 days ago |
| SMA: Bullish | Oct 27, 1:55 PM | 4 days ago |
| SMA: Bearish | Oct 27, 1:50 PM | 4 days ago |
| SMA: Bearish | Oct 27, 1:50 PM | 4 days ago |
| SMA: Bullish | Oct 27, 1:45 PM | 4 days ago |
| SMA: Bullish | Oct 27, 1:45 PM | 4 days ago |
| SMA: Bearish | Oct 27, 1:40 PM | 4 days ago |
| SMA: Bearish | Oct 27, 1:40 PM | 4 days ago |
| SMA: Bullish | Oct 27, 1:20 PM | 4 days ago |
| SMA: Bullish | Oct 27, 1:20 PM | 4 days ago |
| SMA: Bearish | Oct 27, 1:15 PM | 4 days ago |
| SMA: Bearish | Oct 27, 1:00 PM | 4 days ago |
| SMA: Bullish | Oct 27, 12:50 PM | 4 days ago |
| SMA: Bearish | Oct 27, 12:40 PM | 4 days ago |
| SMA: Bearish | Oct 27, 12:15 PM | 4 days ago |
| SMA: Bullish | Oct 27, 12:00 PM | 4 days ago |
| SMA: Bearish | Oct 27, 11:35 AM | 4 days ago |
| MACD: Sell Signal | Oct 27, 11:30 AM | 4 days ago |
| RSI: Overbought | Oct 27, 11:15 AM | 4 days ago |
| RSI: Overbought | Oct 27, 10:45 AM | 4 days ago |
| SMA: Bearish | Oct 27, 10:15 AM | 4 days ago |
| RSI: Overbought | Oct 27, 9:50 AM | 4 days ago |
| RSI: Overbought | Oct 27, 9:40 AM | 4 days ago |
| RSI: Overbought | Oct 26, 3:50 PM | 5 days ago |
| MACD: Buy Signal | Oct 26, 3:35 PM | 5 days ago |
| SMA: Bullish | Oct 26, 3:05 PM | 5 days ago |
| SMA: Bullish | Oct 26, 2:55 PM | 5 days ago |
| SMA: Bearish | Oct 26, 2:50 PM | 5 days ago |
| MACD: Sell Signal | Oct 26, 2:45 PM | 5 days ago |
| SMA: Bearish | Oct 26, 2:40 PM | 5 days ago |
| MACD: Buy Signal | Oct 26, 1:50 PM | 5 days ago |
| SMA: Bullish | Oct 26, 1:10 PM | 5 days ago |
| MACD: Sell Signal | Oct 26, 12:40 PM | 5 days ago |
| SMA: Bearish | Oct 26, 12:30 PM | 5 days ago |
| SMA: Bullish | Oct 26, 11:00 AM | 5 days ago |
| SMA: Bearish | Oct 26, 10:55 AM | 5 days ago |
| SMA: Bullish | Oct 26, 10:50 AM | 5 days ago |
| SMA: Bearish | Oct 26, 10:30 AM | 5 days ago |
Key statistics
- Market cap
- 2.79B
- Enterprise value
- 2.17B
- Trailing P/E
- 0.00
- Forward P/E
- -9.10
- PEG ratio
- 0.00
- Price / sales
- 39.29
- Price / book
- 4.95
- EPS (TTM)
- -3.39
- Beta
- 1.10
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 71.13M
- Revenue growth
- 278.70%
- Free cash flow
- -275.50M
- Total cash
- 981.53M
- Total debt
- 244.73M
- Return on equity
- -65.74%
- Shares outstanding
- 113.29M
- Short % of float
- 16.47%
- 50-day average
- 21.65
- 200-day average
- 21.80
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 36.20 +46.7% upside
Now 24.67
- Target (low)
- 22.00
- Target (mean)
- 36.20
- Target (high)
- 50.00
Ratings (0m) 17 17 buy · 0 hold · 0 sell
- Strong buy3
- Buy14
- Hold0
- Sell0
- Strong sell0
Next earnings
Nov 4, 2026
Expected Nov 4, 2026. Consensus EPS estimate -1.02.
Financials — quick view
VRDN Revenue — quarterly 284.00K
VRDN Net income — quarterly -127.12M
VRDN EPS — quarterly -1.05
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 4, 2026 | Sep 30, 2026 | -1.02 | — | — | — |
| Aug 6, 2026 | Jun 30, 2026 | -1.03 | -1.05 | -0.02 | -1.94% |
| May 5, 2026 | Mar 31, 2026 | -1.06 | -0.90 | +0.16 | +15.09% |
| Feb 26, 2026 | Dec 31, 2025 | -0.90 | -1.08 | -0.18 | -20.00% |
| Nov 5, 2025 | Sep 30, 2025 | -0.82 | -0.34 | +0.48 | +58.54% |
| Aug 6, 2025 | Jun 30, 2025 | -1.00 | -1.00 | 0.00 | 0.00% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 22, 2026 | RBC Capital | main | Outperform | Outperform |
| Aug 7, 2026 | RBC Capital | main | Outperform | Outperform |
| Aug 7, 2026 | Truist Securities | main | Buy | Buy |
| Jun 30, 2026 | RBC Capital | main | Outperform | Outperform |
| Jun 30, 2026 | Truist Securities | main | Buy | Buy |
| Jun 30, 2026 | Wedbush | main | Outperform | Outperform |
About Viridian Therapeutics, Inc.
Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases. It develops IGF-1R therapies to treat thyroid eye disease (TED), including Veligrotrug, a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered, and Elegrobart, a low-volume, infrequently dosed subcutaneous IGF-1R. The company also develops an anti-thyroid-stimulating hormone receptor (TSHR) candidate for the treatment of Graves' disease and TED. Its portfolio of engineered inhibitors of the neonatal Fc receptor (FcFn) includes VRDN-006, a highly selective Fc fragment, and VRDN-008, a half-life extended bispecific FcRn inhibitor comprising an GC fragment and an albumin-binding domain designed to prolong IGG suppression. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. was incorporated in 2010 and is headquartered in Waltham, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- viridiantherapeutics.com
News
- Viridian Intersects 15m of 1.1% CuEq in 1.5km Step-Out Drilling at Kraken Main
- Viridian Therapeutics to Report Third Quarter 2026 Financial Results on November 4, 2026
- Roche Secures FDA Approval for First At-Home Thyroid Eye Disease Therapy
- Viridian Therapeutics, Inc. (NASDAQ:VRDN) Stock Now Rated “Moderate Buy” by Sell-Side Analysts
- RBC Capital Maintains Outperform on Viridian Therapeutics, Raises Price Target to $38
- Viridian Therapeutics: Two Products, One Commercial Buildout
- Viridian Intersects Over 50 Metres of Mineralization from Surface at Kraken Main
- 27,472 Shares in Viridian Therapeutics, Inc. $VRDN Acquired by Jupiter Topco LLC
- Alpha Buying: 4 Biotech Stocks a Healthcare Specialist Is Buying
- Viridian Therapeutics to Participate in the Wells Fargo 21st Annual Healthcare Conference
Your note
Sign in to keep a note on VRDN — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BEETHAM THOMAS W | Chief Operating Officer | Conversion of Exercise of derivative security | Mar 2, 2026 | 13,361 |
| FAIRMOUNT FUNDS MANAGEMENT LLC | Beneficial Owner of more than 10% of a Class of Security | Purchase | May 10, 2026 | 0 |
| HARMON SETH | Chief Financial Officer | Conversion of Exercise of derivative security | Mar 2, 2026 | 7,850 |
| MAHONEY STEPHEN F | Chief Executive Officer | Conversion of Exercise of derivative security | Mar 2, 2026 | 33,349 |
| TOUSIGNANT JENNIFER | Officer | Conversion of Exercise of derivative security | Aug 18, 2026 | 0 |
| TRIPURANENI RADHIKA | Officer | Conversion of Exercise of derivative security | Aug 13, 2026 | 40,000 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| FMR, LLC | 14.66% | 16,604,740 | 409.64M | Jun 29, 2026 |
| Blackrock Inc. | 7.55% | 8,551,488 | 210.97M | Jun 29, 2026 |
| Bellevue Group AG | 5.94% | 6,731,909 | 166.08M | Jun 29, 2026 |
| Paradigm Biocapital Advisors LP | 5.93% | 6,723,788 | 165.88M | Jun 29, 2026 |
| Kynam Capital Management, LP | 5.70% | 6,453,877 | 159.22M | Jun 29, 2026 |
| State Street Corporation | 5.41% | 6,124,976 | 151.10M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.95% | 3,336,970 | 82.32M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.29% | 2,590,081 | 63.90M | Sep 29, 2026 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 2.20% | 2,495,461 | 61.56M | Sep 29, 2026 |
| Fidelity Advisor Series VII-Fidelity Advisor Biotechnology Fund | 1.57% | 1,782,464 | 43.97M | Aug 30, 2026 |
| Fidelity Select Portfolios-Select Health Care Portfolio | 1.32% | 1,500,000 | 37.01M | Aug 30, 2026 |
| T. Rowe Price Health Sciences Fund, Inc. | 1.28% | 1,447,742 | 35.72M | Jun 29, 2026 |